NANJING, China, Feb. 24 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere"or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced the appointment
"Simcere is honored to have Dr. Zhang join the management team," commented Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, "Dr. Zhang is a highly respected leader in the Chinese healthcare industry. I am confident that Dr. Zhang will be a valuable addition to our management team and his professionalism, strategic vision and wealth of experience will help Simcere expand its leadership in China's rapidly growing pharmaceutical market."
Dr. Zhang commented, "I am very excited to join Simcere, a premier pharmaceutical company in China with a deep commitment to quality, innovation and providing China with leading healthcare solutions. I look forward to working with the team here to build a leading enterprise we can all be proud of."
Dr. Zhang has over 18 years of experience in the healthcare industry, most recently serving as a Senior Healthcare Practice Leader in McKinsey's China office focusing on systemic issues impacting the healthcare industry. Dr Zhang worked for over 12 years at Merck Sharp & Dohme in the United States, China, and other regions. During his tenure at Merck Sharp & Dohme, he held positions of responsibility in product manufacturing, supply chain operations and business development. From 2007 to 2008, he served as President of Merck in China. He was also the Greater China Country Managing Director for IMS from 2004-2007.
Dr. Zhang received an MBA degree from the Wharton School of the University of Pennsylvania, a Ph.D. in engineering from the University of Pennsylvania and a bachelor's degree from Harvard University.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
SOURCE Simcere Pharmaceutical Group
Subscribe to our Free Newsletters!
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...View All